{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=10", "query": { "condition": "Adenocarcinoma of Colon", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 706, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T05:26:12.765Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03145909", "title": "A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-176", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-07-03", "completion_date": "2018-11-27", "has_results": false, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • New Haven, Connecticut + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03145909" }, { "nct_id": "NCT07454642", "title": "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vulvar Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Small Cell Carcinoma of Lung", "Colorectal Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "AVA6103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avacta Life Sciences Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2026-03-31", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07454642" }, { "nct_id": "NCT01466504", "title": "Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Colorectal Carcinoma" ], "interventions": [ { "name": "skin punch biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2011-05", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-04-15", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466504" }, { "nct_id": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Squamous Cell Carcinoma of Head and Neck", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Sarcoma", "Endometrial Cancer", "Melanoma", "Castration Resistant Prostatic Cancer", "Cervical Cancer", "Colorectal Cancer", "Gastric Cancer", "Gastro-esophageal Cancer", "Pancreas Cancer", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Platinum-resistant Ovarian Cancer", "Breast Cancer", "Ovarian Cancer", "Esophageal Squamous Cell Cancer (SCC)" ], "interventions": [ { "name": "MGC026 Dose Escalation", "type": "BIOLOGICAL" }, { "name": "MGC026 Dose for Expansion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-03-06", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 7, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06242470" }, { "nct_id": "NCT02611024", "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Glioblastoma", "Soft Tissue Sarcoma (Excluding GIST)", "Endometrial Carcinoma", "Epithelial Ovarian Carcinoma", "Mesothelioma", "Gastroenteropancreatic Neuroendocrine Tumor", "SCLC", "Gastric Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2016-05-06", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 4, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611024" }, { "nct_id": "NCT01111604", "title": "A Study of Ramucirumab or Icrucumab in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Icrucumab", "type": "BIOLOGICAL" }, { "name": "mFOLFOX-6", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2010-08", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 3, "location_summary": "Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbia", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111604" }, { "nct_id": "NCT06586515", "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3962673", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2024-09-12", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 25, "location_summary": "Duarte, California • Santa Monica, California • Denver, Colorado + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586515" }, { "nct_id": "NCT06756035", "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelin-Expressing Tumors", "Epithelial Ovarian Cancer", "Malignant Pleural Mesothelioma, Advanced", "Malignant Peritoneal Mesothelioma, Advanced", "Pancreatic Adenocarcinoma Advanced or Metastatic", "Lung Adenocarcinoma Metastatic", "Cholangiocarcinoma Advanced", "Cholangiocarcinoma Non-resectable", "Mesothelin-expressing Advanced Cancers", "Mesothelin-positive Advanced Malignant Solid Tumors", "Colorectal Cancer" ], "interventions": [ { "name": "CT-95", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Context Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 8, "location_summary": "Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756035" }, { "nct_id": "NCT05194735", "title": "Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gynecologic Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Endometrial Cancer", "Ovarian Carcinoma", "Ovary Neoplasm", "Squamous Cell Lung Cancer", "Adenocarcinoma of Lung", "Adenosquamous Cell Lung Cancer" ], "interventions": [ { "name": "Neoantigen specific TCR-T cell drug product", "type": "BIOLOGICAL" }, { "name": "Aldesleukin (IL-2)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-04-04", "completion_date": "2023-08-14", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194735" }, { "nct_id": "NCT01606124", "title": "Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Adenomas", "Adenocarcinoma of the Colon", "Stage I Colon Cancer", "Stage II Colon Cancer", "Stage III Colon Cancer" ], "interventions": [ { "name": "defined green tea catechin extract", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 39, "start_date": "2012-06", "completion_date": "2015-05-21", "has_results": true, "last_update_posted_date": "2017-10-27", "last_synced_at": "2026-10-13T05:26:12.765Z", "location_count": 3, "location_summary": "Chicago, Illinois • Hines, Illinois • Rochester, Minnesota", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Hines", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606124" } ] }